Olivier Segeral

Dr. Olivier Segeral


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
LFLaurent Ferradini
Laurent Ferradini
VOVara Ouk
Vara Ouk
OSOlivier Segeral
Olivier Segeral
JNJanin Nouhin
Janin Nouhin
ADAnne Dulioust
Anne Dulioust
ENEric Nerrienet
Eric Nerrienet
Background: The number of patients on second‐line highly active antiretroviral therapy (HAART) regimens is increasing in resource‐limited settings. We describe the outcomes after 24 months for patients on LPV/r‐based second‐line regimens followed up by the ESTHER programme in Phnom Penh, Cambodia.Methods: Seventy patients who initiated second‐line HAART regimens more than 24 months earlier were included, and immuno‐virological data analyzed. HIV RNA viral load was determined by real‐time RT‐PCR. HIV‐1 drug resistance was interpreted according to the ANRS algorithm.Results: Of the 70 patients, two were lost to follow up, three died and 65 (92.8%) remained on second‐line treatment after 24 months of follow up (median duration of treatment: 27.4 months). At switch to second‐line, the median CD4 T cell count was 106 cells/mm3 and the median viral load was 4.7 Log10. Second‐line regimens prescribed were ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). The median CD4 T cell gain was +258 cells/mm3 at 24 months (n = 63). After 24 months of follow up, 92.3% (60/65) of the patients presented undetectable viral loads, giving an overall treatment success rate of 85.7% (CI: 75.6‐ 92.0) in intent‐to‐treat analysis.Conclusions: These data suggest that a LPV/r‐based second‐line regimen is associated with a high rate of virological suppression and immune reconstitution after 24 months of follow up in Cambodia.

25 May 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
OSOlivier Segeral
Olivier Segeral
BDBunnet Dim
Bunnet Dim
CDChristine Durier
Christine Durier
SNSovann Nhoueng
Sovann Nhoueng
KCKearena Chhim
Kearena Chhim
LGLaurence Borand for the ANRS-MIE TA PROHM Study Group
Laurence Borand for the ANRS-MIE TA PROHM Study Group

19 March 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
OSOlivier Segeral
Olivier Segeral
BDBunnet Dim
Bunnet Dim
CDChristine Durier
Christine Durier
SPSophearot Prak
Sophearot Prak
KCKearena Chhim
Kearena Chhim
LBLaurence Borand
Laurence Borand
The paucity of hepatitis B virus (HBV) DNA measurement in low-/middle-income countries hinders the identification of HBV-infected pregnant women at risk of perinatal transmission. This study evaluates the validity of an algorithm selecting HBeAg-positive women and HBeAg-negative women with alanine aminotransferase (ALT) ≥40 IU/L as a predictor of high HBV DNA level. All women with reactive samples for hepatitis B surface antigen (HBsAg) were assessed with an SD BIOLINE HBeAg rapid test and HBV DNA quantification was performed. Validities of HBeAg and of the algorithm to identify HBV DNA >2 thresholds (5.3 and 7.3 log10 IU/mL) were evaluated. For the 515 HBsAg-positive women, median age was 29 years, 92 (17.9%) were HBeAg positive, 47 (9.1%) were HBeAg negative with ALT ≥40 IU/L, and 144 (28.0%) had an HBV DNA >5.3 log10 IU/mL. Sensitivity and specificity of HBeAg were 61.8% and 99.2% for HBV DNA >5.3 log10 IU/mL and 81.3% and 96.7% for HBV DNA >7.3 log10 IU/mL. For the algorithm, sensitivity and specificity were 79.2% and 93.3% for HBV DNA level >5.3 log10 IU/mL and 92.7% and 88.1% for HBV DNA >7.3 log10 IU/mL. The AUCs for the algorithm (0.92 and 0.94 for HBV DNA >5.3 and 7.3, respectively) were significantly greater (P < .001) than the AUCs for HBeAg (0.81 and 0.89 for HBV DNA >5.3 and 7.3, respectively). An algorithm using HBeAg and ALT level could be an effective strategy to identify HBV-infected pregnant women at risk of perinatal transmission in countries where HBV DNA quantification is not routinely available.

1 June 2011 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
OSOlivier Segeral
Olivier Segeral
SLSetha Limsreng
Setha Limsreng
JNJanin Nouhin
Janin Nouhin
CHChanRoeurn Hak
ChanRoeurn Hak
SNSopheak Ngin
Sopheak Ngin
ADAnne Dulioust
Anne Dulioust
There are few long-term data on ART-experienced patients in resource-limited settings. We performed a cross-sectional study of HIV-infected patients included in the ESTHER program in Calmette hospital, Phnom Penh, Cambodia, after 36 ± 3 months of cART. Therapeutic, clinical, and immunovirological outcomes were compared between patients who stated they were ART-naive (naive group), dual nucleoside reverse-transcriptase inhibitor (two-NRTI group), or fixed-dose combination of stavudine/lamivudine/nevirapine experienced (three-drug group) at entry to the program. A logistic regression model was used to evaluate the factors associated with virological failure (PCR HIV > 250 copies/ml). Among the 256 patients included in the analysis, 148 (58%) were ART naive while 50 (20%) had previously received two NRTIs and 58 (22%) three drugs. At entry to the program, all the patients received two NRTIs and one nonnucleoside reverse-transcriptase inhibitor (NNRTI). At evaluation, 46 patients (18%) were switched to a protease inhibitor-based regimen (9%, 32%, and 29% of the naive, two-NRTI, and three-drug groups; p < 0.0001). The median CD4 cell count increase was 180/μl overall (IQR: 96–276) and was higher in ART-naive than ART-experienced patients. In the intent-to-treat analysis, virological success was achieved in 83.5%, 67%, and 69% of the naive, two-NRTI, and three-drug groups, respectively ( p = 0.002). Factors associated with virological failure were suboptimal previous ART exposure and WHO immunological failure criteria. The long-term efficacy of first-line cART is maintained in Cambodia. In ART-experienced patients, viral load monitoring needs to be available to establish early virological failure and preserve the potency of second line regimens.

19 March 2018 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
OSOlivier Segeral
Olivier Segeral
ENEric Nerrienet
Eric Nerrienet
SNSansothy Neth
Sansothy Neth
BSBruno Spire
Bruno Spire
VKVohith Khol
Vohith Khol
VSVonthanak Saphonn
Vonthanak Saphonn
Background: Assessment of virological outcomes among HIV-infected patients receiving protease (PR) inhibitor-based second-line regimen are uncommon in Cambodia. The objective of this study is to assess the virological effectiveness of this regimen as well as impact of adherence boosting for patients experiencing virological failure. Methods: The 2PICAM study (Clinicaltrial: NCT01801618) is a cross-sectional study of HIV-infected adults on PR inhibitor-based second-line regimen since at least 6 months, conducted in 13 representative sites, comprising more than 90% of the target population. Adults with HIV RNA above 250 copies/mL (threshold of the assay) at inclusion received boosted adherence counseling during 3 months followed by HIV RNA control. For confirmed virological failure, genotype resistance test was performed and expert committee used results for therapeutic decision. Results: Among the 1,317 adults enrolled, the median duration of second-line regimen was 5 years. At inclusion, 1,182 (89.7%) patients achieved virological success (250 copies/mL). In multivariable analysis, factors associated with virological success were: CD4 cell count between 201 and 350/mm3 (OR: 4.66, 95% CI: 2.57–8.47, p < 0.0001) and >350/mm3 (OR: 6.67, 95% CI: 4.02–11.06, p < 0.0001), duration of PI-based regimen >2 years (OR: 1.64, 95% CI: 1.03–2.62, p = 0.037), ATV-containing regimen (0R: 1.65, 95% CI: 1.04–2.63, p = 0.034) and high level of adherence (OR: 2.41, 95% CI: 1.07–5.41, p = 0.033). After adherence counseling, 63 (46.7%) patients were rescued while 72 (53.3%) were not. For the 54 patients with genotype resistance tests available, high or intermediate levels of resistance to lopinavir, atazanavir, and darunavir were reported for 13 (24%), 12 (22.2%), and 2 (3.7%) patients, respectively. Change to an alternative PR inhibitor-based regimen was recommended for 17 patients and to third-line regimen, including integrase inhibitors for 12. Conclusion: This study reports high rate of virological suppression of second-line regimen and importance of adherence boosting prior to deciding any change of ART regimen. Genotype resistance tests appear necessary to guide decisions. Such information was of great importance for National HIV Program to adapt guidelines and program needs for third-line regimen.

1 October 2021 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
OSOlivier Segeral
Olivier Segeral
WPWathanakpiseychoupoan Phirum
Wathanakpiseychoupoan Phirum
OKOusa Khan
Ousa Khan
HCHyna Chea
Hyna Chea
SSSaren Sovann
Saren Sovann
LBLaurence Borand
Laurence Borand